Shufang Medicine assists Xiangya Second Hospital in launching the first 5D smart diagnosis and treatment center for pulmonary hypertension in China

Shanghai September 26, 2021/PRNewswire/ - September 25, at the 8th Xiaoxiang Pulmonary Vascular Disease Forum and the 2021 Hunan Provincial Health Management Association Pulmonary Vascular Disease Health Management Professional Committee Academic Annual Meeting, Central South University, Hunan Professor Li Jiang, director of the Pulmonary and Vascular Disease Sub-specialty Department of the Department of Cardiology, Ya Second Hospital, officially announced that, leveraging the advantages of digital tools in remote, real-time, automation, and intelligence, the Second Xiangya Hospital officially launched the first domestic pulmonary hypertension "5D smart diagnosis and treatment center

Li Jiang introduced that the "5D" of the "5D Smart Diagnosis and Treatment Center" refers to doctor network, data mining, disease management, smart wearable (Device link), and digital empowerment (Data plus).

"In the era of pulmonary hypertension diagnosis and treatment 1.

As a supporter of the project, Shufang Pharmaceutical, an innovative company focusing on the development and commercialization of new drugs for rare diseases, and the left-hand doctor, a leading medical artificial intelligence company, jointly assisted the Second Xiangya Hospital to build a diagnosis and treatment covering pulmonary hypertension before, during and after diagnosis.

The pictures are: Zhang Chao, founder and CEO of Left Hand Doctor, Li Jiang, Director of Pulmonary and Vascular Disease Subspecialty, Department of Cardiology, Second Xiangya Hospital of Central South University, Yan Zhiyu, Chairman of Shufang Medicine, Xu Qing, Head of Innovative Business Development, Li Dongxue, Product Manager, and Xiangya, Central South University Luo Jun, Attending Physician, Department of Cardiology, Ya Second Hospital

AI empowers a new model of doctor-patient connection

Pulmonary hypertension is a rare and fatal cardiopulmonary vascular disease.

Clinical data shows that the current diagnosis and treatment of patients with pulmonary hypertension has yet to be improved

"As a standardized diagnosis and treatment center for pulmonary hypertension in Hunan Province, the birth of the 5D smart diagnosis and treatment model for pulmonary hypertension will greatly improve this dilemma

Li Jiang, Director, Pulmonary and Vascular Disease Subspecialty, Department of Cardiology, The Second Xiangya Hospital, Central South University

The advantages of the 5D smart diagnosis and treatment model are first reflected in the efficient management and information transmission of patients

"As a technical partner of the project, we are looking forward to using this milestone product to promote the establishment of an AI doctor-driven and efficient doctor-patient interaction model in China, breaking down multiple barriers such as time and space for patients with rare diseases, and allowing them to enjoy high-quality products.

Zhang Chao, founder and CEO of Left Hand Doctor

AI technology helps clinical research on rare diseases

Another bright spot that has attracted attention is the promotion of the 5D smart diagnosis and treatment center in clinical research

"AI technology allows us to see more possibilities

Yan Zhiyu, co-founder, chairman and CEO of Shufang Pharmaceutical

"Using artificial intelligence and digital medical technology to empower disease diagnosis and treatment and clinical research is the direction we have been practicing

Source: Shufang Medicine